Daniel O Claassen1, Wery P M van den Wildenberg2, Madaline B Harrison3, Nelleke C van Wouwe4, Kristen Kanoff4, Joseph S Neimat5, Scott A Wylie4. 1. Department of Neurology, Vanderbilt University, Nashville, TN, United States. Electronic address: daniel.claassen@vanderbilt.edu. 2. Department of Psychology, University of Amsterdam, Netherlands. 3. Department of Neurology, University of Virginia, Charlottesville, VA, United States. 4. Department of Neurology, Vanderbilt University, Nashville, TN, United States. 5. Department of Neurosurgery, Vanderbilt University, Nashville, TN, United States.
Abstract
BACKGROUND: Parkinson disease (PD) patients treated with dopamine agonist therapy can develop maladaptive reward-driven behaviors, known as impulse control disorder (ICD). In this study, we assessed if ICD patients have evidence of motor-impulsivity. METHODS: We used the stop-signal task in a cohort of patients with and without active symptoms of ICD to evaluate motor-impulsivity. Of those with PD, 12 were diagnosed with ICD symptoms (PD-ICD) and were assessed before clinical reduction of dopamine agonist medication; 12 were without symptoms of ICD [PD-control] and taking equivalent dosages of dopamine agonist. Levodopa, if present, was maintained in both settings. Groups were similar in age, duration, and severity of motor symptoms, levodopa co-therapy, and total levodopa daily dose. All were tested in the dopamine agonist medicated and acutely withdrawn (24 h) state, in a counterbalanced manner. Primary outcome measures were mean reaction time to correct go trials (go reaction time), and mean stop-signal reaction time (SSRT). RESULTS: ICD patients produce faster SSRT than both Healthy Controls, and PD-Controls. Faster SSRT in ICD patients is apparent in both dopamine agonist medication states. Also, we show unique dopamine medication effects on Go Reaction time (GoRT). In dopamine agonist monotherapy patients, dopamine agonist administration speeds GoRT. Conversely, in those with levodopa co-therapy, dopamine agonist administration slows. DISCUSSION: PD patients with active ICD symptoms are significantly faster at stopping initiated motor actions, and this is not altered by acute dopamine agonist withdrawal. In addition, the effect of dopamine agonist on GoRT is strongly influenced by the presence or absence of levodopa, even though levodopa co-therapy does not appear to influence SSRT. We discuss these findings as they pertain to the multifaceted definition of 'impulsivity,' the lack of evidence for motor-impulsivity in PD-ICD, and dopamine effects on motor-control in PD.
BACKGROUND:Parkinson disease (PD) patients treated with dopamine agonist therapy can develop maladaptive reward-driven behaviors, known as impulse control disorder (ICD). In this study, we assessed if ICDpatients have evidence of motor-impulsivity. METHODS: We used the stop-signal task in a cohort of patients with and without active symptoms of ICD to evaluate motor-impulsivity. Of those with PD, 12 were diagnosed with ICD symptoms (PD-ICD) and were assessed before clinical reduction of dopamine agonist medication; 12 were without symptoms of ICD [PD-control] and taking equivalent dosages of dopamine agonist. Levodopa, if present, was maintained in both settings. Groups were similar in age, duration, and severity of motor symptoms, levodopa co-therapy, and total levodopa daily dose. All were tested in the dopamine agonist medicated and acutely withdrawn (24 h) state, in a counterbalanced manner. Primary outcome measures were mean reaction time to correct go trials (go reaction time), and mean stop-signal reaction time (SSRT). RESULTS:ICDpatients produce faster SSRT than both Healthy Controls, and PD-Controls. Faster SSRT in ICDpatients is apparent in both dopamine agonist medication states. Also, we show unique dopamine medication effects on Go Reaction time (GoRT). In dopamine agonist monotherapy patients, dopamine agonist administration speeds GoRT. Conversely, in those with levodopa co-therapy, dopamine agonist administration slows. DISCUSSION: PDpatients with active ICD symptoms are significantly faster at stopping initiated motor actions, and this is not altered by acute dopamine agonist withdrawal. In addition, the effect of dopamine agonist on GoRT is strongly influenced by the presence or absence of levodopa, even though levodopa co-therapy does not appear to influence SSRT. We discuss these findings as they pertain to the multifaceted definition of 'impulsivity,' the lack of evidence for motor-impulsivity in PD-ICD, and dopamine effects on motor-control in PD.
Authors: Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang Journal: Arch Neurol Date: 2010-05
Authors: Dara G Ghahremani; Buyean Lee; Chelsea L Robertson; Golnaz Tabibnia; Andrew T Morgan; Natalie De Shetler; Amira K Brown; John R Monterosso; Adam R Aron; Mark A Mandelkern; Russell A Poldrack; Edythe D London Journal: J Neurosci Date: 2012-05-23 Impact factor: 6.167
Authors: Scott A Wylie; Daniel O Claassen; Hilde M Huizenga; Kerilyn D Schewel; K Richard Ridderinkhof; Theodore R Bashore; Wery P M van den Wildenberg Journal: J Cogn Neurosci Date: 2012-05-09 Impact factor: 3.225
Authors: Paula Trujillo; Nelleke C van Wouwe; Ya-Chen Lin; Adam J Stark; Kalen J Petersen; Hakmook Kang; David H Zald; Manus J Donahue; Daniel O Claassen Journal: Cortex Date: 2019-01-29 Impact factor: 4.027
Authors: Daniel S Peterson; Katrijn Smulders; Martina Mancini; John G Nutt; Fay B Horak; Brett W Fling Journal: J Int Neuropsychol Soc Date: 2020-12-09 Impact factor: 2.892
Authors: Leah G Mann; Kaitlyn R Hay; Alexander K Song; Steven P Errington; Paula Trujillo; David H Zald; Yan Yan; Hakmook Kang; Gordon D Logan; Daniel O Claassen Journal: J Neurosci Date: 2021-11-08 Impact factor: 6.709
Authors: Brian N Haagensen; Damian M Herz; David Meder; Kristoffer H Madsen; Annemette Løkkegaard; Hartwig R Siebner Journal: Neuroimage Clin Date: 2020-06-25 Impact factor: 4.881
Authors: Alice Martini; Denise Dal Lago; Nicola M J Edelstyn; James A Grange; Stefano Tamburin Journal: Front Neurol Date: 2018-08-28 Impact factor: 4.003
Authors: Alice Martini; Simon J Ellis; James A Grange; Stefano Tamburin; Denise Dal Lago; Greta Vianello; Nicola M J Edelstyn Journal: J Neural Transm (Vienna) Date: 2017-11-08 Impact factor: 3.575